FDA Law Blog
JUNE 15, 2022
Circuit, but today, the Supreme Court reversed again and upheld the District Court’s opinion in American Hospital Assn v. S. _ (2022). The statute sets this “average price” as ASP plus 6%. After finding that the statute was subject to statutory review, the Court turned to the merits of the case.
FDA Law Blog
SEPTEMBER 30, 2022
As we reported, on November 5, 2020, the District Court held that the relator could not plausibly plead the requisite scienter because Forest’s interpretation of the ambiguous statute was objectively reasonable and CMS did not warn Forest away from that interpretation through authoritative guidance. Burr , 551 U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Patently O
FEBRUARY 24, 2022
Rather, any new grant this term will very likely be pushed back to the October 2022 Term for hearing and decision. Still, there are a number of important patent cases pending before the court. 21-746 (CVSG requested February 22, 2022). 2022)(forthcoming). Lets talk them through. Qualcomm Incorporated , No.
Patently O
AUGUST 8, 2022
” Unfortunately, due to a series of Supreme Court decisions, patent eligibility law in the United States has become confused, constricted, and unclear in recent years. This has led to inconsistent case decisions, uncertainty in innovation and investment communities, and unpredictable business outcomes.
Patently O
MARCH 3, 2022
In 2021, the Supreme Court sided with the patentee in holding that the AIA trial system violated the Appointments Clause of the U.S. The Court concluded that PTAB judges were wielding the substantial power of the U.S. Oral arguments in this round of the appeal are set for March 30, 2022. by Dennis Crouch. Arthrex, Inc.
At the Lectern
MAY 1, 2024
California Commerce Club : Does California’s test for determining whether a party has waived its right to compel arbitration by engaging in litigation remain valid after the United States Supreme Court decision in Morgan v. 2022) _ U.S. _ [142 S.Ct. The court granted review in August 2022. Sundance, Inc.
Patently O
SEPTEMBER 21, 2022
In its 2022 Caltech decision, the Federal Circuit overturned its prior Shaw precedent and found that the estoppel broadly applies to all claims challenged in an IPR and all grounds “which reasonably could have been asserted” against the petitioned claims. 2022) (“Caltech”). 2022) (“Caltech”).
Expert insights. Personalized for you.
.png)
52 
Let's personalize your content